Jennifer Jarrett

October 13, 2026

DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.

October 13, 2026

SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.

October 16, 2026

Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.